[Immunity in human schistosomiasis: hope for a vaccine].
Schistosomiasis remains a major worldwide public health problem in several endemic areas despite implementation of control measures. Vaccination would be an effective, long-term treatment option for future control of schistosomiasis. Although several parasite antigens have been identified as schistosomiasis vaccine candidates, major hurdles must still be overcome to develop a vaccine suitable for clinical trials in the field. Better understanding of immune responses to Schistosoma infection in both animal models and humans suggests that development of a vaccine is possible. The purpose of this review is to summarize the mechanisms of protective immunity against Schistosoma infection and to provide perspective on the development of a vaccine.
Kouriba
B
B
Département d'épidémiologie des affections parasitaires, Faculté de médecine, de pharmacie et d'odontostomatologie, Bamako, Mali. kouriba@mrtcbko.org
Traore
B
B
Diemert
D
D
Thera
M A
MA
Dolo
A
A
Tounkara
A
A
Doumbo
O
O
D056704:Adaptive Immunity; D000818:Animals; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D016052:Protozoan Vaccines / Q000627:therapeutic use*; D012547:Schistosoma / Q000276:immunology; D012552:Schistosomiasis / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control
D007074:Immunoglobulin G; D016052:Protozoan Vaccines; D007073:Immunoglobulin E